The Division of Antiviral products has laid out nonbinding recommendations about the acceptable NGS platforms and the kinds of information it's looking for.
AmoyDx and Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development.
The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.
Danaher is offering 11 million shares of its common stock at $123 per share and 1.5 million shares of its mandatory convertible preferred stock at $1,000 per share.
Danaher is financing the deal with $3 billion from an equity offering, cash on hand, and proceeds from an issuance of debt and/or new credit facilities.
Freshly minted as a "unicorn," the Utah healthcare data analytics powerhouse is building up a new life sciences division to aid biotech development and precision medicine.
The company, which employs 300 people, axed 30 jobs in the US and 25 jobs from its overseas operations as it refocuses on therapeutic development.
The Jamaican Lion strain was sequenced and assembled with DASH funding, and will be published via "crypto-incentivized, blockchain-recorded peer review."
Genetic and phenotypic data for Million Veteran Program participants led to loss-of-function changes in a gene inhibited by cilostazol.
Organizers of a data analysis challenge remain hopeful that a recent update to the Connectivity Map resource will lead to breakthroughs in DILI detection by next year.
A new analysis finds some cancers receive more nonprofit dollars than others.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.